foxo4-dri senolytic human trial 2024 FOXO4‐DRI is inclined to kill TGF‐β‐induced myofibroblasts in vitro FOXO4-DRI induces keloid senescent fibroblast
FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Therapeutic targeting of senescent cells in the CNS Nature Reviews Drug Discovery The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications ES2 rapidly destroys TP53 FOXO4 foci leading to TP53 mediated Download Scientific Diagram
Pay in 4 interest-free payments of $7.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23



